drugset / Trial / NCT04346355

Efficacy of Early Administration of Tocilizumab in COVID-19 Patients

NCT04346355

Phase 2 Terminated 126 enrolled Azienda USL Reggio Emilia - IRCCS
RandomizedParallel-groupOpen-labelTreatment

Summary

The clinical study aims at assessing whether early administration of Tocilizumab compared to late administration of Tocilizumab can reduce the number of patients with COVID-19 pneumonia who require mechanical ventilation. The clinical study includes patients with recent-onset COVID-19 pneumonia who require hospital care, but not invasive or semi-invasive mechanical ventilation procedures.

Timeline

Start
2020-03-31
Primary completion
2020-06-06
Completion
2020-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous

Indications